[{"from": "human", "value": "Describe this molecule. [C][C][C][C][C][C][C][C][=Branch1][C][=O][N][C@H1][Branch1][=Branch2][C][N][C][C][C][C][Ring1][Branch1][C@@H1][Branch1][P][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][C][O][Ring1][Branch2][O].[C][C][C][C][C][C][C][C][=Branch1][C][=O][N][C@H1][Branch1][=Branch2][C][N][C][C][C][C][Ring1][Branch1][C@@H1][Branch1][P][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][C][O][Ring1][Branch2][O].[C@@H1][Branch1][#Branch2][C@H1][Branch1][=Branch1][C][=Branch1][C][=O][O][O][Branch1][=Branch1][C][=Branch1][C][=O][O][O]"}, {"from": "gpt", "value": "The molecule is a recombinant human \u03b1-galactosidase A similar to [agalsidase alfa]. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta. Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.  Agalsidase beta was granted FDA approval on 24 April 2003."}]